IQVIA与COVID-19研究的澳大利亚医学研究所合作,以支持前线医疗保健工作者必威手机APP

5 20, 2020

Randomized, double-blind clinical study will test Hydroxychloroquine as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (NYSE: IQV) today announced that theWalter and Eliza Hall Institute of Medical Research是澳大利亚领先的生物医学研究组织,已选择IQVIA来管理Covid Shield,这是一项II/III期随机,双盲的临床研究,对前线医疗工作者进行预防性护理,与COVID-19与Covid-19的大流行作战。必威手机APP

“ IQVIA很荣幸能与Walter和Eliza Hall研究所合作进行这项临床试验,以期在这次COVID-19大流行期间,为我们的高风险前线医疗保健和盟军护理人员提供预防性护理。”必威手机APPiqvia。“作为人类数据科b必威学公司,IQVIA具有独特的位置,可以通过我们无与伦比的数据,高级分析,变革性技术和广泛的领域专业知识来支持这项研究,以保持医疗保健的前进。”必威手机APP

The COVID SHIELD clinical study will test an expanded indication for generic Hydroxychloroquine (HCQ) as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19. Local hospitals across Australia will administer HCQ or a placebo to approximately 2,250 healthcare professionals who are currently looking after COVID-19 patients.

“The COVID SHIELD trial is focused on our frontline and allied healthcare workers who are at an increased risk of infection due to repeated exposure caring for sick patients. Our collective aim is to help these people stay safe, well and able to continue in their vital roles,” said Marc Pellegrini, principal investigator, Walter and Eliza Hall Institute of Medical Research. “We are pleased to work with IQVIA in this fight against COVID-19 and are hopeful this Australian-first trial will provide a definitive answer to the question of whether hydroxychloroquine is effective as a prophylaxis, or prevention, against contracting COVID-19.”

为了简化这项试验,而不会在前线医疗工作者或临床团队中承受不当风险和负担,IQVIA将使用虚拟临床工具和技术。必威官方在线必威手机APP这些虚拟技术包括远程监视,E必威官方在线conent,ETMF和电子源。参与这项研究的医疗保健工作者必威手机APP将位于包括维多利亚州,新南威尔士州和南澳大利亚州以及澳大利亚首都地区在内的几个澳大利亚州。

For more information and how to get involved about the COVID SHIELD study, visithttps://covidshield.com.au.

关于伊克维亚

IQVIA(NYSE:IQV)是生命科学行业的高级分析,技术解决方案和合同研究服务的全球领先提供商。IQVIA通过IMS Health and五分之一的合并形成,应用必威手机APP了人类数据科学 - 利用数据科学的分析性严格和清晰度为人类科学的范围,使b必威公司能够重新想象并开发新的方法,并开发了新的方法,以实现临床发展和商业化,商业化,商业化的新方法加快创新并加速医疗保健结果的改善。必威手机APPIQVIA在IQVIA Cor手机版必威e™的支持下,在大规模分析,变革技术和广泛的领域专业知识以及执行能力的交集中提供了独特而可betway必威怎么提款行的见解。IQVIA拥有大约67,000名员工,在100多个国家 /地区进行运营。

IQVIA是保护个体患者隐私的全球领导者。该公司使用各种各样的隐私技术和保障措施来保护个人隐私,同时生成和分析信息,以帮助医疗保健利益相关者识别疾病必威官方在线模式,并与获得更好结果所需的精确治疗路径和治疗相关。必威手机APPIQVIA的见解betway必威怎么提款和执行能力可以帮助生物技术,医疗设备和制药公司,医学研究人员,政府机构,付款人和其他医疗保健利益相关者对疾病,人类行为和科学进步的更深入了解,以促进他们迈向固执的道路。必威手机APP要了解更多信息,请访问m.kurtisdurfey.com.

Click here to subscribe to Mobile Alerts for IQVIA.

Tor Constantino,IQVIA媒体关系(tor.constantino@iqvia.com)
+1.484.567.6732

Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144

Source: IQVIA

联系我们
お問い合わせ CONTACT US
お問い合わせ CONTACT US

メール EMAIL US

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our免费列表.

Media Inquiries

Please use this form to reach out to our media team with inquiries. Thank you.